Because deletion of CDC42 had no effect on cell proliferation and only a weak influence on acute inflammation, CDC42 could be an attractive target for the treatment of age-associated diseases without promoting tumor formation or compromising normal immune function. The gene discussed is CDC42; the disease is neoplasm.